Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

ABCG2- and ABCB1 inhibition using supratherapeutic doses of erlotinib: clinical implications in the treatment of CNS metastases.

van de Stadt EA, Yaqub M, Bahce I, Hendrikse NH.

J Nucl Med. 2019 Oct 4. pii: jnumed.119.235705. doi: 10.2967/jnumed.119.235705. [Epub ahead of print] No abstract available.

PMID:
31586007
2.

Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?

El-Khouly FE, Veldhuijzen van Zanten SEM, Santa-Maria Lopez V, Hendrikse NH, Kaspers GJL, Loizos G, Sumerauer D, Nysom K, Pruunsild K, Pentikainen V, Thorarinsdottir HK, Rutkauskiene G, Calvagna V, Drogosiewicz M, Dragomir M, Deak L, Kitanovski L, von Bueren AO, Kebudi R, Slavc I, Jacobs S, Jadrijevic-Cvrlje F, Entz-Werle N, Grill J, Kattamis A, Hauser P, Pears J, Biassoni V, Massimino M, Lopez Aguilar E, Torsvik IK, Joao Gil-da-Costa M, Kumirova E, Cruz-Martinez O, Holm S, Bailey S, Hayden T, Thomale UW, Janssens GOR, Kramm CM, van Vuurden DG.

J Neurooncol. 2019 Oct;145(1):177-184. doi: 10.1007/s11060-019-03287-9. Epub 2019 Sep 14.

3.

Reply to: Quantification of 18F-DCFPyL Uptake: TBR versus Patlak's Analysis.

Jansen BHE, Yaqub MM, Cysouw MCF, Vis AN, van Moorselaar RJA, Hendrikse NH, Boellaard R, Hoekstra OS, Oprea-Lager DE.

J Nucl Med. 2019 Aug 26. pii: jnumed.119.234047. doi: 10.2967/jnumed.119.234047. [Epub ahead of print] No abstract available.

PMID:
31451491
4.

Satisfaction with information on nilotinib treatment in chronic myeloid leukemia patients.

Boons CCLM, Tromp VNMF, Neppelenbroek NJM, Timmers L, van Schoor NM, Swart EL, Hendrikse NH, Janssen JJWM, Hugtenburg JG.

Acta Oncol. 2019 Jun;58(6):891-896. doi: 10.1080/0284186X.2019.1585944. Epub 2019 Mar 25. No abstract available.

PMID:
30905234
5.

Feasibility of and patients' perspective on nilotinib dried blood spot self-sampling.

Boons CCLM, Timmers L, Janssen JJWM, Swart EL, Hugtenburg JG, Hendrikse NH.

Eur J Clin Pharmacol. 2019 Jun;75(6):825-829. doi: 10.1007/s00228-019-02640-1. Epub 2019 Feb 7.

PMID:
30729257
6.

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.

Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, van Dongen GAMS, Boellaard R, Du S, Hayes W, Smith R, Windhorst AD, Hendrikse NH, Poot A, Vugts DJ, Thunnissen E, Morin P, Lipovsek D, Donnelly DJ, Bonacorsi SJ, Velasquez LM, de Gruijl TD, Smit EF, de Langen AJ.

Nat Commun. 2018 Nov 7;9(1):4664. doi: 10.1038/s41467-018-07131-y.

7.

Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and 11C-Erlotinib PET.

Verheijen RB, Yaqub M, Sawicki E, van Tellingen O, Lammertsma AA, Nuijen B, Schellens JHM, Beijnen JH, Huitema ADR, Hendrikse NH, Steeghs N.

J Nucl Med. 2018 Jun;59(6):973-979. doi: 10.2967/jnumed.117.195800. Epub 2017 Nov 24.

8.

Patient satisfaction with information on oral anticancer agent use.

Boons CCLM, Timmers L, van Schoor NM, Swart EL, Hendrikse NH, Janssen JJWM, Hugtenburg JG.

Cancer Med. 2018 Jan;7(1):219-228. doi: 10.1002/cam4.1239. Epub 2017 Nov 23.

9.

Effective Drug Delivery in Diffuse Intrinsic Pontine Glioma: A Theoretical Model to Identify Potential Candidates.

El-Khouly FE, van Vuurden DG, Stroink T, Hulleman E, Kaspers GJL, Hendrikse NH, Veldhuijzen van Zanten SEM.

Front Oncol. 2017 Oct 30;7:254. doi: 10.3389/fonc.2017.00254. eCollection 2017.

10.

Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood sampling.

Boons CCLM, Chahbouni A, Schimmel AM, Wilhelm AJ, den Hartog YM, Janssen JJWM, Hendrikse NH, Hugtenburg JG, Swart EL.

J Pharm Pharmacol. 2017 Oct;69(10):1265-1274. doi: 10.1111/jphp.12757. Epub 2017 Jun 23.

PMID:
28643375
11.

Successful Use of [14C]Paracetamol Microdosing to Elucidate Developmental Changes in Drug Metabolism.

Mooij MG, van Duijn E, Knibbe CAJ, Allegaert K, Windhorst AD, van Rosmalen J, Hendrikse NH, Tibboel D, Vaes WHJ, de Wildt SN.

Clin Pharmacokinet. 2017 Oct;56(10):1185-1195. doi: 10.1007/s40262-017-0508-6.

12.

Cytotoxic Effects of the Therapeutic Radionuclide Rhenium-188 Combined with Taxanes in Human Prostate Carcinoma Cell Lines.

Lange R, ter Heine R, van Wieringen WN, Tromp AM, Paap M, Bloemendal HJ, de Klerk JM, Hendrikse NH, Geldof AA.

Cancer Biother Radiopharm. 2017 Feb;32(1):16-23. doi: 10.1089/cbr.2016.2129. Epub 2017 Jan 24.

PMID:
28118029
13.

Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases.

Lange R, Ter Heine R, Knapp RF, de Klerk JM, Bloemendal HJ, Hendrikse NH.

Bone. 2016 Oct;91:159-79. doi: 10.1016/j.bone.2016.08.002. Epub 2016 Aug 2. Review. Erratum in: Bone. 2017 Dec;105:315.

PMID:
27496068
14.

Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study.

Lange R, Overbeek F, de Klerk JM, Pasker-de Jong PC, van den Berk AM, Ter Heine R, Rodenburg CJ, Kooistra A, Hendrikse NH, Bloemendal HJ.

Nuklearmedizin. 2016 Sep 26;55(5):188-95. doi: 10.3413/Nukmed-0828-16-05. Epub 2016 Jul 22.

PMID:
27443809
15.

Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET.

Bahce I, Yaqub M, Smit EF, Lammertsma AA, van Dongen GA, Hendrikse NH.

Lung Cancer. 2017 May;107:1-13. doi: 10.1016/j.lungcan.2016.05.025. Epub 2016 May 31. Review.

16.

Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?

Jauw YW, Menke-van der Houven van Oordt CW, Hoekstra OS, Hendrikse NH, Vugts DJ, Zijlstra JM, Huisman MC, van Dongen GA.

Front Pharmacol. 2016 May 24;7:131. doi: 10.3389/fphar.2016.00131. eCollection 2016. Review.

17.

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC.

Bahce I, Yaqub M, Errami H, Schuit RC, Schober P, Thunnissen E, Windhorst AD, Lammertsma AA, Smit EF, Hendrikse NH.

EJNMMI Res. 2016 Dec;6(1):10. doi: 10.1186/s13550-016-0169-8. Epub 2016 Feb 9.

18.

Quantitative and Simplified Analysis of 11C-Erlotinib Studies.

Yaqub M, Bahce I, Voorhoeve C, Schuit RC, Windhorst AD, Hoekstra OS, Boellaard R, Hendrikse NH, Smit EF, Lammertsma AA.

J Nucl Med. 2016 Jun;57(6):861-6. doi: 10.2967/jnumed.115.165225. Epub 2016 Feb 4.

19.

Altered GABAA receptor density and unaltered blood-brain barrier [11C]flumazenil transport in drug-resistant epilepsy patients with mesial temporal sclerosis.

Froklage FE, Postnov A, Yaqub MM, Bakker E, Boellaard R, Hendrikse NH, Comans EF, Schuit RC, Schober P, Velis DN, Zwemmer J, Heimans JJ, Lammertsma AA, Voskuyl RA, Reijneveld JC.

J Cereb Blood Flow Metab. 2017 Jan;37(1):97-105. Epub 2015 Nov 19.

20.

Quantification of 11C-Laniquidar Kinetics in the Brain.

Froklage FE, Boellaard R, Bakker E, Hendrikse NH, Reijneveld JC, Schuit RC, Windhorst AD, Schober P, van Berckel BN, Lammertsma AA, Postnov A.

J Nucl Med. 2015 Nov;56(11):1730-5. doi: 10.2967/jnumed.115.157586. Epub 2015 Aug 20.

21.

Pediatric microdose and microtracer studies using 14C in Europe.

Turner MA, Mooij MG, Vaes WH, Windhorst AD, Hendrikse NH, Knibbe CA, Kõrgvee LT, Maruszak W, Grynkiewicz G, Garner RC, Tibboel D, Park BK, de Wildt SN.

Clin Pharmacol Ther. 2015 Sep;98(3):234-7. doi: 10.1002/cpt.163. Epub 2015 Jul 17.

PMID:
26095095
22.

Microdosing of a Carbon-14 Labeled Protein in Healthy Volunteers Accurately Predicts Its Pharmacokinetics at Therapeutic Dosages.

Vlaming ML, van Duijn E, Dillingh MR, Brands R, Windhorst AD, Hendrikse NH, Bosgra S, Burggraaf J, de Koning MC, Fidder A, Mocking JA, Sandman H, de Ligt RA, Fabriek BO, Pasman WJ, Seinen W, Alves T, Carrondo M, Peixoto C, Peeters PA, Vaes WH.

Clin Pharmacol Ther. 2015 Aug;98(2):196-204. doi: 10.1002/cpt.131. Epub 2015 May 19.

PMID:
25869840
23.

Detecting resistance in EGFR-mutated non-small-cell lung cancer after clonal selection through targeted therapy.

Kuiper JL, Bahce I, Voorhoeve C, Yaqub M, Heideman DA, Thunnissen E, Paul MA, Postmus PE, Hendrikse NH, Smit EF.

Per Med. 2015 Mar;12(2):63-66. doi: 10.2217/pme.14.64.

PMID:
29754538
24.

Synthesis of [3-N-(11) C-methyl]temozolomide via in situ activation of 3-N-hydroxymethyl temozolomide and alkylation with [(11) C]methyl iodide.

Eriksson J, Van Kooij R, Schuit RC, Froklage FE, Reijneveld JC, Hendrikse NH, Windhorst AD.

J Labelled Comp Radiopharm. 2015 Mar;58(3):122-6. doi: 10.1002/jlcr.3251. Epub 2015 Feb 17.

PMID:
25693064
25.

Quantification of 18F-fluorocholine kinetics in patients with prostate cancer.

Verwer EE, Oprea-Lager DE, van den Eertwegh AJ, van Moorselaar RJ, Windhorst AD, Schwarte LA, Hendrikse NH, Schuit RC, Hoekstra OS, Lammertsma AA, Boellaard R.

J Nucl Med. 2015 Mar;56(3):365-71. doi: 10.2967/jnumed.114.148007. Epub 2015 Feb 12.

26.

Drug composition matters: the influence of carrier concentration on the radiochemical purity, hydroxyapatite affinity and in-vivo bone accumulation of the therapeutic radiopharmaceutical 188Rhenium-HEDP.

Lange R, de Klerk JMH, Bloemendal HJ, Ramakers RM, Beekman FJ, van der Westerlaken MML, Hendrikse NH, Ter Heine R.

Nucl Med Biol. 2015 May;42(5):465-469. doi: 10.1016/j.nucmedbio.2015.01.007. Epub 2015 Jan 22.

PMID:
25662844
27.

Untangling the web of European regulations for the preparation of unlicensed radiopharmaceuticals: a concise overview and practical guidance for a risk-based approach.

Lange R, ter Heine R, Decristoforo C, Peñuelas I, Elsinga PH, van der Westerlaken MM, Hendrikse NH.

Nucl Med Commun. 2015 May;36(5):414-22. doi: 10.1097/MNM.0000000000000276. Review.

PMID:
25646703
28.

Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care.

Mammatas LH, Verheul HM, Hendrikse NH, Yaqub M, Lammertsma AA, Menke-van der Houven van Oordt CW.

Cell Oncol (Dordr). 2015 Feb;38(1):49-64. doi: 10.1007/s13402-014-0194-4. Epub 2014 Sep 24. Review.

PMID:
25248503
29.

Pediatric microdose study of [(14)C]paracetamol to study drug metabolism using accelerated mass spectrometry: proof of concept.

Mooij MG, van Duijn E, Knibbe CA, Windhorst AD, Hendrikse NH, Vaes WH, Spaans E, Fabriek BO, Sandman H, Grossouw D, Hanff LM, Janssen PJ, Koch BC, Tibboel D, de Wildt SN.

Clin Pharmacokinet. 2014 Nov;53(11):1045-51. doi: 10.1007/s40262-014-0176-8.

30.

Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases.

ter Heine R, Lange R, Breukels OB, Bloemendal HJ, Rummenie RG, Wakker AM, de Graaf H, Beekman FJ, van der Westerlaken MM, Malingré MM, Wielders JP, van den Berg L, Hendrikse NH, de Klerk JM.

Int J Pharm. 2014 Apr 25;465(1-2):317-24. doi: 10.1016/j.ijpharm.2014.01.034. Epub 2014 Feb 19.

PMID:
24560635
31.

Radiation dose of the P-glycoprotein tracer 11C-laniquidar.

Postnov A, Froklage FE, van Lingen A, Reijneveld JC, Hendrikse NH, Windhorst AD, Schuit RC, Eriksson J, Lammertsma AA, Huisman MC.

J Nucl Med. 2013 Dec;54(12):2101-3. doi: 10.2967/jnumed.113.120857. Epub 2013 Oct 3.

32.

Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [¹¹C]docetaxel and positron emission tomography.

van der Veldt AA, Lubberink M, Mathijssen RH, Loos WJ, Herder GJ, Greuter HN, Comans EF, Rutten HB, Eriksson J, Windhorst AD, Hendrikse NH, Postmus PE, Smit EF, Lammertsma AA.

Clin Cancer Res. 2013 Aug 1;19(15):4163-73. doi: 10.1158/1078-0432.CCR-12-3779. Epub 2013 Apr 25.

33.

[¹¹C]Sorafenib: radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer.

Poot AJ, van der Wildt B, Stigter-van Walsum M, Rongen M, Schuit RC, Hendrikse NH, Eriksson J, van Dongen GA, Windhorst AD.

Nucl Med Biol. 2013 May;40(4):488-97. doi: 10.1016/j.nucmedbio.2013.02.002. Epub 2013 Mar 20.

34.

Pilot study on the feasibility of PET/CT lymphoscintigraphy with 89Zr-nanocolloidal albumin for sentinel node identification in oral cancer patients.

Heuveling DA, van Schie A, Vugts DJ, Hendrikse NH, Yaqub M, Hoekstra OS, Karagozoglu KH, Leemans CR, van Dongen GA, de Bree R.

J Nucl Med. 2013 Apr;54(4):585-9. doi: 10.2967/jnumed.112.115188. Epub 2013 Feb 1.

35.

Imaging of TKI-target interactions for personalized cancer therapy.

Poot AJ, Slobbe P, Hendrikse NH, Windhorst AD, van Dongen GA.

Clin Pharmacol Ther. 2013 Mar;93(3):239-41. doi: 10.1038/clpt.2012.242. Epub 2012 Dec 12. No abstract available.

PMID:
23340475
36.

Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status.

Bahce I, Smit EF, Lubberink M, van der Veldt AA, Yaqub M, Windhorst AD, Schuit RC, Thunnissen E, Heideman DA, Postmus PE, Lammertsma AA, Hendrikse NH.

Clin Cancer Res. 2013 Jan 1;19(1):183-93. doi: 10.1158/1078-0432.CCR-12-0289. Epub 2012 Nov 7.

37.

[11C]Flumazenil brain uptake is influenced by the blood-brain barrier efflux transporter P-glycoprotein.

Froklage FE, Syvänen S, Hendrikse NH, Huisman MC, Molthoff CF, Tagawa Y, Reijneveld JC, Heimans JJ, Lammertsma AA, Eriksson J, de Lange EC, Voskuyl RA.

EJNMMI Res. 2012 Mar 28;2:12. doi: 10.1186/2191-219X-2-12.

38.

Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.

Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, Verheul HM, Serné EH, Lammertsma AA, Smit EF.

Cancer Cell. 2012 Jan 17;21(1):82-91. doi: 10.1016/j.ccr.2011.11.023.

39.

Absolute quantification of [(11)C]docetaxel kinetics in lung cancer patients using positron emission tomography.

van der Veldt AA, Lubberink M, Greuter HN, Comans EF, Herder GJ, Yaqub M, Schuit RC, van Lingen A, Rizvi SN, Mooijer MP, Rijnders AY, Windhorst AD, Smit EF, Hendrikse NH, Lammertsma AA.

Clin Cancer Res. 2011 Jul 15;17(14):4814-24. doi: 10.1158/1078-0432.CCR-10-2933. Epub 2011 Jul 12.

40.

Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer.

van der Veldt AA, Hendrikse NH, Harms HJ, Comans EF, Postmus PE, Smit EF, Lammertsma AA, Lubberink M.

J Nucl Med. 2010 Nov;51(11):1684-90. doi: 10.2967/jnumed.110.079137. Epub 2010 Oct 18.

41.

Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function.

de Klerk OL, Willemsen AT, Bosker FJ, Bartels AL, Hendrikse NH, den Boer JA, Dierckx RA.

Psychiatry Res. 2010 Aug 30;183(2):151-6. doi: 10.1016/j.pscychresns.2010.05.002.

PMID:
20620031
42.

Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients.

van der Veldt AA, Hendrikse NH, Smit EF, Mooijer MP, Rijnders AY, Gerritsen WR, van der Hoeven JJ, Windhorst AD, Lammertsma AA, Lubberink M.

Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1950-8. doi: 10.1007/s00259-010-1489-y. Epub 2010 May 27.

43.

Re: Sarcoid-like reaction to malignancy on whole-body integrated 18F-FDG PET/CT: prevalence and disease pattern.

van der Veldt AA, Comans EF, Thunnissen FB, Hendrikse NH, Smit EF, van der Hoeven JJ.

Clin Radiol. 2010 Jan;65(1):94-6; author reply 96-7. doi: 10.1016/j.crad.2009.08.011. Epub 2009 Nov 11. No abstract available.

PMID:
20103429
44.

Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier.

de Klerk OL, Willemsen AT, Roosink M, Bartels AL, Hendrikse NH, Bosker FJ, den Boer JA.

Int J Neuropsychopharmacol. 2009 Aug;12(7):895-904. doi: 10.1017/S1461145709009894. Epub 2009 Feb 19.

PMID:
19224656
45.

Peripheral metabolism of [(18)F]FDDNP and cerebral uptake of its labelled metabolites.

Luurtsema G, Schuit RC, Takkenkamp K, Lubberink M, Hendrikse NH, Windhorst AD, Molthoff CF, Tolboom N, van Berckel BN, Lammertsma AA.

Nucl Med Biol. 2008 Nov;35(8):869-74. doi: 10.1016/j.nucmedbio.2008.09.002.

PMID:
19026948
46.

Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistance.

van der Veldt AA, Luurtsema G, Lubberink M, Lammertsma AA, Hendrikse NH.

Curr Pharm Des. 2008;14(28):2914-31. Review.

PMID:
18991710
47.

Positron emission tomography for modeling pathophysiological processes in vivo.

Hendrikse NH, Luurtsema G, van der Veldt AA, Lubberink M.

Curr Opin Drug Discov Devel. 2008 Sep;11(5):717-25. Review.

PMID:
18729023
48.

[11C]docetaxel and positron emission tomography for noninvasive measurements of docetaxel kinetics.

van der Veldt AA, Lammertsma AA, Hendrikse NH.

Clin Cancer Res. 2007 Dec 15;13(24):7522; author reply 7522-3. No abstract available.

49.

Irradiation of rat brain reduces P-glycoprotein expression and function.

Bart J, Nagengast WB, Coppes RP, Wegman TD, van der Graaf WT, Groen HJ, Vaalburg W, de Vries EG, Hendrikse NH.

Br J Cancer. 2007 Aug 6;97(3):322-6. Epub 2007 Jul 3.

50.

In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically.

Ishiwata K, Kawamura K, Yanai K, Hendrikse NH.

J Nucl Med. 2007 Jan;48(1):81-7.

Supplemental Content

Loading ...
Support Center